Business
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the fin
About this update from Aclaris Therapeutics, Inc.
[{"type":"image","alt":"Aclaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aclaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtMq4w0NL5RX6oHluykk3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8","width":300,"height":126}},"lazy":false},{"type":"text","content":"WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026.","length":540,"tagName":"p"},{"type":"text","content":"Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be available on the Events page of the Company’s website: https://investor.aclaristx.com/events. The webcast will be archived on the same page for 30 days following the event. If you would rather access the call via telephone: To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.","length":651,"tagName":"p"},{"type":"text","content":"Cautionary Note Regarding Forward-Looking Statements","length":52,"tagName":"p"},{"type":"text","content":"Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations...